1. Introduction

Difficult to diagnose, difficult to treat and difficult to get medications are embarrassing situations for patients with rare diseases not only in China but also for rare disease patients all over the world. Due to previous hospital procurement restrictions, physician prescription restrictions, and outpatient reimbursement restrictions, having no access to drugs is a problem crying for solution for patients with rare diseases in China (1). Generally, accessibility includes availability, which involves research, development and market access of drugs, adaptability, which involves the construction of a diagnosis and treatment system, and affordability, which involves the pricing and inclusion in medical insurance (2-4). Thus, the following discussion about the current situation of accessibility to rare disease drugs in China will be from three perspectives, availability, adaptability and affordability.

2. The current national policies on orphan drugs

China's attention to rare diseases started late. There are no special rare disease laws and policies at the national level, and there is no specific rare disease drug (including orphan drug) policy. However, in recent years, as society's attention to rare diseases has increased, the importance of orphan drugs has gradually appeared in various policy documents (Table 1).

It can be seen from various policies that China has increased the accessibility of orphan drugs and implemented priority evaluation. Especially, the evaluation of rare disease drugs is required to be done in 3 months, which has greatly accelerated the speed of new drug listings. In the importing process, value added tax is levied at 3%. In terms of basic research, the publication of National Rare Disease List involved
<table>
<thead>
<tr>
<th>Item</th>
<th>Category</th>
<th>Effective time</th>
<th>Policy &amp; Regulation</th>
<th>Content about Rare Diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Availability</td>
<td>Development and imitation of drugs</td>
<td>2012 (5)</td>
<td>The Notice of the State Council on National Drug Safety During the 12th Five-Year Plan issued by the State Council.</td>
<td>To encourage the development of orphan drugs and suitable dosage forms for children.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2017 (6)</td>
<td>The Opinions of the State Council on Reform of the System of Evaluation, Review and Approval of Drugs and Medical Devices issued by the General Office of the State Council.</td>
<td>To support the development of drugs and medical devices for rare diseases.</td>
</tr>
<tr>
<td>Registration and approval</td>
<td>2007 (7)</td>
<td>The Measures for the Administration of Drug Registration issued by former China Food and Drug administration.</td>
<td>Special approval for new drugs with obvious clinical efficacy in the treatment of AIDS, malignant tumors, rare diseases etc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2013 (9)</td>
<td>The Opinions of the China Food and Drug Administration on deepening the reform of evaluation and approval systems and encouraging innovation on drugs issued by former China Food and Drug Administrations.</td>
<td>Prioritize and speed up the evaluation of rare disease drugs.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2015 (10)</td>
<td>The Opinions of the State Council on Reform of the System of Evaluation, Review and Approval of Drugs and Medical Devices issued by the State Council.</td>
<td>Accelerated evaluation and approval of innovative drugs for the prevention and treatment of diseases such as rare diseases, sub-neoplastic diseases, AIDS and major infectious diseases.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2016 (11)</td>
<td>The Notice of the General Office of the State Council on issuing the 2015 Major Task List on Deepening the Medical and Health Care System reform issued by the General Office of the State Council.</td>
<td>Further smooth the special channel for evaluation and approval of rare disease drugs and clinical urgently needed drugs.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2017 (13)</td>
<td>The Policies of the China Food and Drug Administration regarding Encouraging Innovation and Accelerating the Evaluation and Approval Systems on Drugs and Medical Devices (Consultation Paper) issued by the former China Food and Drug Ministration.</td>
<td>Applicants for rare disease treatments and medical devices may apply for clinical trials for reduction and exemption; and rare-drug treatment drugs and medical devices that have been approved for marketing abroad, supplement relevant research within the prescribed time after listing.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2017 (14)</td>
<td>Opinions of the China Food and Drug Administration on encouraging innovative implementation of prioritized evaluation and approval on drugs issued by the former China Food and Drug Administration.</td>
<td>Drug registration for rare diseases can be included in the scope of prioritized evaluation and approval.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2018 (15)</td>
<td>Notice of the National Medical Products Administration and the National Health Commission on Optimizing Review and Approval of Registration of Medical Products issued by the National Medical Product Administration and the National Health Commission.</td>
<td>Orphan drugs can submit clinical trial data obtained overseas and directly apply for drug listing registration, which meeting the requirements of the Drug Registration Management Measures and related documents may directly approve the import.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2018 (16)</td>
<td>Interim Measures of the National Medical Products Administration for Protection of Pharmaceutical Test Data (Consultation Paper) issued by the former China Food and Drug Administration.</td>
<td>Orphan drugs are listed as the target of data protection and a 6-year data protection period is granted to them since the indication firstly approved in China.</td>
<td></td>
</tr>
</tbody>
</table>
urgently needed drugs for rare disease treatment were included in the "imperatively needed clinical drugs that should be researched and developed" and 9 research and development projects were carried out with a central government's financial budget of more than RMB 50 million (25). On May 29, 2019, the Center for Drug Evaluation, National Medical Product Administration published "The Basic Consideration of Using Real World Evidence to Support the Research and Development of Drugs (Consultation Paper)" and proposed that the clinical trials of rare disease drugs can use the real world data formed by the natural disease cohort as an external control to help the research (26).

However, due to the weak foundation of China's drug research and development, coupled with slow progress in basic research and no special incentives from the country (such as internationally-recognized research and development grants, tax reduction policies, etc.), the company lacks research and development incentives. At present, there are no new drugs for rare diseases coming out in China.

121 diseases, which greatly increased the attention to rare diseases (18).

3. The current accessibility to rare disease drugs in China

3.1. Availability of rare disease drugs

3.1.1. The level of research, development and imitation is still low

In 2012, "the Notice of the State Council on National Drug Safety During the 12th Five-Year Plan" (5) encouraged research and development of rare disease drugs and suitable dosages for children. Furthermore, "the Opinions of the State Council on Reform of the System of Evaluation, Review and Approval of Drugs and Medical Devices" (6) encouraged research and development of pharmaceuticals and medical devices for the treatment of rare disease. In the 2017 and 2018 new drug project application guidelines, urgent needed drugs for rare disease treatment were included in the "imperatively needed clinical drugs that should be researched and developed" and 9 research and development projects were carried out with a central government's financial budget of more than RMB 50 million (25). On May 29, 2019, the Center for Drug Evaluation, National Medical Product Administration published "The Basic Consideration of Using Real World Evidence to Support the Research and Development of Drugs (Consultation Paper)" and proposed that the clinical trials of rare disease drugs can use the real world data formed by the natural disease cohort as an external control to help the research (26). However, due to the weak foundation of China's drug research and development, coupled with slow progress in basic research and no special incentives from the country (such as internationally-recognized research and development grants, tax reduction policies, etc.), the company lacks research and development incentives. At present, there are no new drugs for rare diseases coming out in China.
3.1.2. Registration and approval are speeding up and the number is increasing

In terms of speed, it was proposed that rare disease drugs should be reviewed and evaluated within three months (27). From the quantity perspective, more than 40% of around 400 orphan drugs listed in the US haven't been applied in China (28). Due to the lack of a unified definition of rare disease in the world and there is no clear definition of rare diseases in China, China Organization for Rare Disorders used the National Rare Disease List as a sample to organize the pharmaceuticals globally listed for the 121 rare diseases from the list (Figure 1) (1). From the result, out of the 121 rare diseases, 47 diseases also have no therapeutic drugs (mainly in the US/EU/Japan). However, there are 79 drugs outside the country but not listed in the country, involving 21 diseases. There are still 35 listed drugs that have no indications from the list.

It is worth noting that in 2018, 13 rare disease drugs involving 10 rare diseases were successfully applied for listing through priority review and approval. There are 20 rare disease drugs involving 12 rare diseases included in the list of Clinically-needed Foreign New Drugs (first batch) (19) issued by Centre for Drug Evaluation, National Medical Products Administration. In 2019, 14 rare disease drugs were included in the list of clinically urgent new drugs (second batch) (20).

3.2. Adaptability of rare disease drugs

3.2.1. Basic research projects started

Although basic research on rare diseases in China is weak (29), with the continuous attention of society to rare diseases, the basic data is constantly improving. In December 2016, the China Research Hospital Association Rare Diseases Branch was established in Beijing. At the same time, the National Key Research and Development Program "Rare Disease Clinical Cohort Study" and "Rare Diseases Precision Diagnosis and Treatment Technology and Clinical Standard Research" project were officially launched (30). In June 2017, the National Key Research and Development Program "Chinese Severe Diseases and Rare Diseases Clinical and Life Omics Database" was launched (31). In the same year, the National Rare Disease Registration System (NRDRS) was officially launched, which would create an information resource platform and a biobank with gene, protein, metabolomics and molecular imaging diagnostic platforms. By the end of 2018, NRDRS had registered more than 100 rare diseases and more than 30,000 cases (32).

3.2.2. The current situation of diagnosis and treatment is not optimistic

Although in recent years, China has made many breakthroughs in the construction of a rare disease diagnosis and treatment system, in 2017, Shanghai edited the first rare disease monograph "Treatable Rare Disease", which provided diagnosis and treatment guidelines for 117 different rare diseases (33). In 2018, the China Alliance of Rare Diseases was established which became the first national and non-profit communication platform for rare diseases (34). In 2019, the Rare Diseases Diagnosis and Treatment Guidelines (2019 Edition) involving 121 rare diseases were released. In the same year, the National Health Commission announced that 324 hospitals with strong diagnosis and treatment ability as well as relatively more cases would be selected to establish a rare disease diagnosis and treatment collaboration network (35). However, patients with rare diseases still face the dilemma of having no pharmaceuticals for treatment. Among the more than 7,000 known rare diseases, less

Table 2. The rare disease drugs which are reimbursed by local government

<table>
<thead>
<tr>
<th>Province/City</th>
<th>The Rare Diseases Involved</th>
<th>Main Policy</th>
</tr>
</thead>
</table>
| Qingdao (39)  | Multiple sclerosis: Recombinant human interferon for injection (β-1b); Hyperphenylalanemia: Sapropterin Dihydrochloride Tablets; Idiopathic Pulmonary Artery Hypertension: Bosentan Tablets; Gaucher disease: Imiglucerase for Injection; Haemophilia: Recombinant Human Coagulation Factor IX for Injection. | •) Supplementary Medical Insurance Funds reimbursed 80%.
•) Large amount of security section, personal burden of more than 50,000 yuan/year, reimbursed 70%, annual maximum payment was 200,000 yuan.
•) Insured people in low-and middle-income families can also enjoy the special medical subsidy provided by the civil administration. |
| Shanghai (40) | Children's Hospitalization Fund: Pompeii Disease, Fabre Disease, Gaucher Disease, Mucopolysaccharidosis; Special Rescue Funds for Lysosomal Storage: Diseases Associated with Lysosomal Storage. | •) Children's Hospitalization Funds reimbursed RMB10,000 (children only).
•) Special Rescue Funds for Lysosomal Storage provide relief for the remaining co-payments of patients. |
| Zhejiang (41) | Gaucher Disease: Imiglucerase for Injection; Hyperphenylalanemia: Sapropterin Dihydrochloride Tablets; Idiopathic Pulmonary Fibrosis: Nintedanib; Idiopathic Pulmonary Artery Hypertension: Ambrisentan tablets; Amyotrophic Lateral Sclerosis: Riluzole. | •) Medical expenses other than medicare reimbursement were resolved by financial arrangement funds through special assistance.
•) Special funds were subsidized by provincial finance through civil assistance. |
| Henan (42)    | Haemophilia, Phenylketonuria etc. | •) Included in the list of severe diseases |
| Shenzhen (43) | Idiopathic Pulmonary Arterial Hypertension: Bosentan Tablets; Crohn's Disease: Infliximab for Injection. | •) Included in the supplementary medical insurance list, reimburse 70% |
| Chengdu (44)  | Idiopathic Pulmonary Arterial Hypertension: Bosentan Tablets; Crohn's Disease: Infliximab for Injection | •) Included in the medical insurance drug list for severe diseases, reimburse 70% and the limitation is 150,000 yuan at most. |

than 10% of the rare diseases have approved therapeutic drugs or interventions. From 2014 to 2018, the Chinese Organization for Rare Disorders surveyed 5,810 patients with rare diseases (36). The results showed that 42% of patients did not receive any treatment, and most of the patients who received treatment failed to take a sufficient amount of medicine in a timely way. In the National Rare Disease List, only 53 rare diseases have therapeutic drugs listed, and 43 kinds of drugs involving 33 rare diseases have been listed in China but have not registered corresponding rare disease indications, which indirectly leads to clinicians making over-estimated prescriptions. But this undoubtedly brings great risk of medication. Finally, the "last mile" of rare disease drugs is still full of challenges, such as bidding and purchasing, hospital purchase list, prescription restrictions, outpatient reimbursement, and restrictions on designated medical institutions as well as pharmacies.

3.3. Affordability of rare disease drugs

3.3.1. Pricing policy needs to be improved

Since June 2015, China has eliminated the way in which the government manages the price of medicines in a unified manner. The price of different types of drugs will be set by different methods. For rare diseases drugs, there are the following types: those included in the medical insurance list, the National Healthcare Security Administration formulates the medical insurance payment standard; for drugs with patents and exclusive production, the price is determined by multiple parties to negotiate and set the price; for other drugs, the enterprises will mainly price them independently. Because the current domestic rare disease drugs are mainly imported from abroad, most of them are patented drugs or exclusive products, which leads to a high price. For this reason, the State Council issued "the Notice of the Customs Tariff Commission of the State Council on the Provisional Import and Export Tariff Rate and Other Tariff Rate Adjustment Plan for 2019" (37), involving some raw materials of rare disease drugs to implement zero tariff. In 2019, the Ministry of Finance issued the "Notice by the Ministry of Finance, the General Administration of Customs, the State Administration of Taxation and the National Medical Products Administration of the VAT Policies on Drugs for Rare Diseases" (38), the value added tax of 21 rare diseases and 4 active pharmaceutical ingredients were reduced. Despite this, high-priced drugs still face difficulties entering medical insurance list, while low-cost drugs face a crisis of being discontinued or even having production stopped.

3.3.2. Number of rare disease drugs continuously increases

In 2017, China first introduced two orphan drugs into the medical insurance catalogue through national
negotiations (39), and achieved a certain breakthrough in market access for orphan drugs. By the end of 2018, out of 121 rare diseases, 50 drugs for rare diseases had been included in medical insurance, of which 17 were classified as Class A medical insurance (Drugs in Class A medical insurance are fully reimbursed) and 33 were classified as Class B medical insurance (Drugs in Class B medical insurance are partly reimbursed. The percentage depends on the local policies and the type of drugs).

Some provinces and cities in China have guaranteed orphan drugs excluded from the national medical insurance list, but this exploration is still limited to a small number of provinces and cities and a small number of rare diseases/drugs (Table 2).

4. Discussion and Suggestions

Despite the fact that rare diseases have received much attention and favorable policies have been introduced in China, drugs for rare diseases have been imported, but they are mainly concentrated in the drug registration and approval process, and other processes are still weak (Figure 2).

4.1. Formulate a tilt policy for orphan drug research and development

From the perspective of research and development of orphan drugs, although China has introduced relevant incentive policies, it lacks substantial preferential measures, resulting in a lack of research and development incentives. At present, most of the rare diseases in the world lack effective treatment, and there are a large number of blank areas that need to be filled, which leaves room for Chinese biomedical innovation. Therefore, it is recommended to learn
from foreign experience, the government provides orphan drug research and development grants (46) and guidance information consulting services for developers (47). Also, tax reduction or exemption for orphan drug research and development enterprises can be an effective way. After the drug is launched, by determining market monopoly power, tilt pricing and inclusion in medical insurance can help companies to improve their return on investment and product competitiveness to attract more companies to invest in research and development (48). Additionally, support local imitations for patent invalidation of new drugs.

4.2. Establish special drug classification and approval

In the drug registration and approval process, China has accelerated registration through priority evaluation and accelerated approval, which has greatly facilitated the introduction of orphan drugs abroad. It is recommended to give priority to the evaluation and approval of drugs with clear diagnosis and treatable rare diseases. Learn from the experience of introducing anticancer drugs, further render preferential tariffs and VAT. Establish special approval channels for some blood products related drugs to secure rare disease patients, which rely on blood products for intervention or treatment.

4.3. Implement dynamic adjustment to the National Rare Disease List and construct a centers of excellence

Basic research work and diagnosis and treatment capacity construct can directly affect the accessibility of rare diseases drugs. At present, a large-scale clinical cohort study and registration system has been established at the national level (49), but the number of rare diseases is numerous. Therefore, it is recommended to further strengthen the previous epidemiological research and related basic research, implement the dynamic update of the rare disease list. Strengthen the construction of diagnosis and treatment ability, and gradually establish the state and provincial center of excellence to further empower medical staffs to identify, diagnose, and treat rare diseases.

4.4. Try implementation of multi-party co-payment security mode

The cost of rare disease drugs is extremely high. With the main policy of medical insurance in China, how to reduce the burden of patients' drug costs is an important issue to be urgently solved. It is recommended to learn from local experience and establish a government-led, medical insurance covered and multi-party payment security model. First, set up a special fund within medical insurance for rare diseases, encourage social forces to participate through multi-funding and risk sharing. The second is to include rare disease drugs in medical insurance in batches, and to ensure that the rare drugs with the exact effect are preferentially included in the medical insurance. Finally, health technology assessment methods should be introduced to establish a special evaluation process for orphan drugs (50).

In conclusion, rare diseases are not just medical problems, but also social problems. How to promote innovation in the pharmaceutical industry? How to ensure the equity, equality and efficiency and how to solve the sustainability of funds? Despite the valuable experience of other countries and regions, and the exploration of domestic success in some provinces and cities, how to secure the accessibility of rare disease drugs based on the Chinese context still needs much effort.

Acknowledgements

This study was supported by a grant from the Shanghai Municipal Health Commission for a Special Research Project related to Health Policies entitled "Study on the disease burden of and social security for the vulnerable population in Shanghai (Project number: 19Y04017)".

References

9. The former China Food and Drug Administrations. The Opinions of the China Food and Drug Administration on deepening the reform of evaluation and approval systems and encouraging innovation on drugs. http://zw.hainan.gov.cn/data/news/2013/02/9412/ (accessed April 6,


(Received April 15, 2019; Revised May 29, 2019; Accepted May 31, 2019)